FMC Corporation
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a FMC research report →
Range $4 – $21
Price Chart
About the company
FMC Corporation functions as an agricultural science enterprise, delivering products for crop safeguarding, plant wellness, and professional pest and turf management. The company is responsible for creating, commercializing, and selling various crop protection chemicals, including insecticides, herbicides, and fungicides, alongside biologicals, crop nutrition supplements, and seed treatment solutions. These innovations are employed in farming to boost harvest quantity and quality by mitigating diverse insect infestations, weed growth, and plant ailments.
- CEO
- Pierre R. Brondeau
- IPO
- 1980
- Employees
- 5,500
- HQ
- Philadelphia, PA, US
Get TickerSpark's AI analysis on FMC
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $487.13M
- P/E
- -0.13
- Fwd P/E
- 4.21
- PEG
- 0.00
- P/S
- 0.19
- P/B
- -29.41
- EV/EBITDA
- -6.62
- Div Yield
- 7.46%
- Gross Margin
- 23.36%
- Op Margin
- -86.89%
- Net Margin
- -148.38%
- ROE
- -308.88%
- ROIC
- -46.12%
Latest fiscal year · YoY change
- Revenue
- $3.47B-18.3%
- Gross Profit
- $1.28B-18.7%
- Op Income
- $-1,886,600,000
- Net Income
- $-2,238,900,000-758.7%
- EPS
- $-17.88-754.9%
- OCF Growth
- -112.0%
- FCF Growth
- -129.3%
- 52W High
- $18.29
- 52W Low
- $3.89
- 50D MA
- $7.33
- 200D MA
- $11.72
- Beta
- 0.50
- RSI (14)
- 28
- Avg Volume
- 6.06M
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
FMC posted a very weak third quarter due to major commercial actions and softer volumes, but management says those actions should reset the business model and support an earnings inflection in 2027-2028.· October 30, 2026
- Q3 revenue was $106 million, adjusted EBITDA was negative $559 million, and adjusted EPS was negative $4.41, all heavily affected by commercial actions.
- Excluding the commercial actions and India, underlying sales were $745 million and underlying EBITDA was $113 million, both below the low end of prior guidance.
- FMC booked $639 million of revenue impact and $672 million of EBITDA impact from the commercial actions, including an approximately $500 million non-cash charge for the North America pricing/rebate reset.
- Q4 guidance calls for revenue of $1.04 billion to $1.14 billion, adjusted EBITDA of $210 million to $230 million, and adjusted EPS of $0.56 to $0.70.
- Management now expects 2026 free cash flow of negative $350 million to negative $150 million, and sees 2027 adjusted EBITDA of at least $650 million to as much as $730 million.
- The company also expects 2028 adjusted EBITDA of approximately $760 million to $840 million, with stronger cash generation as restructuring spending falls.
Third quarter 2026 revenue was $106 million, including approximately $639 million of impact from the commercial actions. Excluding the commercial actions and India, underlying sales were $745 million, below the low end of the original guidance due to lower-than-expected volumes. Third quarter adjusted EBITDA was negative $559 million, including approximately $672 million from the commercial actions; excluding those actions, underlying EBITDA was $113 million. Adjusted EPS was negative $4.41. For the fourth quarter, FMC guided to revenue of $1.04 billion to $1.14 billion, adjusted EBITDA of $210 million to $230 million, and adjusted EPS of $0.56 to $0.70. For full-year 2026, free cash flow is expected to be negative $350 million to negative $150 million, interest expense $270 million to $280 million, and D&A $160 million to $170 million.
Pierre Brondeau said the quarter exposed a larger channel inventory issue than initially expected, especially in North America, where customers are holding very low inventory values and delaying replenishment. He framed the October 15 commercial actions as necessary to remove that constraint by simplifying pricing and reducing the value of high-priced inventory in the channel. His tone was defensive about the quarter but confident that the actions, plus prior restructuring and new products, can restore growth and improve competitiveness in 2027 and 2028.
Andrew Sandifer detailed the financial impact of the quarter, including $639 million charged against revenue and $672 million against EBITDA from the commercial actions. He also cited $73.6 million of third-quarter interest expense, year-end 2026 interest expense guidance of $270 million to $280 million, and free cash flow guidance of negative $350 million to negative $150 million, including expected restructuring spending of $180 million. He said gross debt ended the quarter at about $4.2 billion, cash on hand at $736 million, and net debt at about $3.4 billion, while noting covenant compliance and expecting net debt of about $3.1 billion by year-end if the India and Delaware transactions close.
Analysts focused heavily on cash flow, especially how much of the $175 million channel-inventory adjustment would hit future cash collections and whether the $500 million North America pricing reset would affect cash. Management said the $500 million charge is non-cash and does not change 2026 cash flow, while the $175 million is likely a 4- to 6-quarter cash headwind, though not necessarily a full long-term cash loss because some of it may accelerate collections or avoid bad debt. Other questions addressed SG&A and R&D, with Pierre saying SG&A has already been materially restructured and that the company wants to hold R&D spending roughly flat, potentially with more partnerships in the future.
Management argued the commercial actions should unblock demand by lowering channel inventory values and making FMC pricing more competitive downstream. They also pointed to a pipeline of new actives, including fluindapyr, Isoflex, Dodhylex, and rimisoxafen, plus manufacturing footprint changes that should lower costs and support growth. Pierre described initial customer feedback as very positive and said 2027 should mark a financial inflection.
The quarter showed a steep operational setback, with weak volumes and major charges that drove adjusted EBITDA deeply negative. Management also acknowledged a challenging market backdrop, including strained grower margins, competition, demand uncertainty, and potential El Niño-related impacts. Cash flow remains pressured by lower sales, lower collections, and restructuring spending, and the company said 2027 guidance is not yet formal because the transition is still underway.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 98.9%
- Shares Outstanding
- 125.23M
- Float Shares
- 123.82M
of shares held by institutions
439 13F filers
Buy/sell ratio 10.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Congressional trading
Senate and House stock disclosures for FMC, newest first.
| Member | Type | Traded | |
|---|---|---|---|
| Daniel Milton NewhouseHouse · WA04 | Sell | Jul 10, 26 | Filing → |
| Lisa C. McClainHouse · MI09 | Sell | Oct 31, 25 | Filing → |
| Lisa C. McClainHouse · MI09 | Buy | Oct 30, 25 | Filing → |
| Lisa C. McClainHouse · MI09 | Sell | Oct 30, 25 | Filing → |
| Lisa C. McClainHouse · MI09 | Buy | Sep 25, 25 | Filing → |
| Ro KhannaHouse · CA17 | Sell | Sep 9, 24 | Filing → |
| Daniel Milton NewhouseHouse · WA04 | Buy | Apr 10, 24 | Filing → |
| Thomas Richard CarperSenate · DE | Buy | Dec 11, 23 | Filing → |
| Ro KhannaHouse · CA17 | Buy | Oct 31, 23 | Filing → |
| Ro KhannaHouse · CA17 | Sell | Sep 6, 23 | Filing → |
| Ro KhannaHouse · CA17 | Buy | Aug 3, 23 | Filing → |
| Ro KhannaHouse · CA17 | Sell | Apr 10, 23 | Filing → |
| Ro KhannaHouse · CA17 | Sell | Nov 2, 22 | Filing → |
| Ro KhannaHouse · CA17 | Buy | Nov 3, 22 | Filing → |
Source: public STOCK Act disclosures. Filed weeks after the trade — a lagging signal, not a real-time one.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Blackrock, Inc. | 21.41M | ▼ 126.91K |
| Vanguard Group Inc | 12.97M | ▼ 1.82M |
| Aqr Capital Management LLC | 8.02M | ▼ 1.24M |
| Vanguard Portfolio Management LLC | 7.62M | ▼ 98.76K |
| State Street Corp | 6.49M | ▼ 19.47K |
| American Century Companies Inc | 6.07M | ▲ 1.01M |
| Vanguard Capital Management LLC | 5.64M | ▼ 119.73K |
| D. E. Shaw & Co., Inc. | 4.91M | ▼ 1.11M |
| Geode Capital Management, LLC | 3.20M | ▼ 80.73K |
| Morgan Stanley | 2.96M | ▲ 840.54K |
| Two Sigma Investments, LP | 2.83M | ▲ 447.91K |
| Ubs Group AG | 2.61M | ▲ 91.28K |
Held by 468 ETFs
Biggest fund positions in FMC by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Nov 10, 26 | Tack Luc Jules R | buy | 2,514 |
| Nov 3, 26 | Scanlan Jacqueline | sell | 4,930 |
| Oct 15, 26 | CORDEIRO EDUARDO E | other | 169 |
| Oct 15, 26 | DAVIDSON CAROL ANTHONY | other | 107 |
| Oct 15, 26 | Fortmann Kathy Lynn | other | 130 |
| Oct 15, 26 | Johnson KLynne | other | 239 |
| Oct 15, 26 | BARRY MICHAEL F | other | 15 |
| Oct 15, 26 | Raines John Mitchell | other | 62 |
| Oct 15, 26 | MERKT STEVEN T | other | 53 |
| Oct 15, 26 | Verduin Patricia | other | 65 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our FMC coverage
Recent articles, reports, and earnings notes.
Want a deeper read on FMC?
Generate a full analyst-grade report — bull/bear case, price targets, valuation depth, and a complete financial breakdown.
Gainey McKenna & Egleston Announces A Class Action Lawsuit Has Been Filed Against FMC Corporation (FMC)
globenewswire.com · Nov 20
Securities Fraud Lawsuit Filed Against FMC Corporation: The Law Offices of Frank R. Cruz Outlines Lead Plaintiff Deadline
businesswire.com · Nov 20
CLASS ACTION NOTICE: FMC Corp. Investors Should Contact Block & Leviton to Possibly Recover Losses
newsfilecorp.com · Nov 20
FMC DEADLINE ALERT: Faruqi & Faruqi, LLP Reminds FMC (NYSE: FMC) Investors of Securities Class Action Lawsuit Deadline on January 19, 2027
businesswire.com · Nov 20
FMC INVESTOR ALERT: Class Action Lawsuit Filed on Behalf of FMC Corporation Investors – Holzer & Holzer, LLC Encourages Investors With Losses to Contact the Firm
globenewswire.com · Nov 20
Investor Alert: Robbins LLP Informs Investors of the FMC Corporation Class Action Lawsuit
businesswire.com · Nov 20
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors It Has Filed a Complaint to Recover Losses Suffered by Purchasers of FMC Corporation Common Stock and Sets a Lead Plaintiff Deadline of January 19, 2027
globenewswire.com · Nov 19
Block & Leviton Encourages FMC Investors to Contact the Firm about Ongoing Investigation
newsfilecorp.com · Nov 19
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.
